Angiotensin 1-7 (Ang 1-7) is a seven-amino-acid peptide hormone generated by ACE2 enzyme cleavage of angiotensin I or Ang II. It functions as the primary counter-regulatory molecule in the RAA-system, binding the MAS receptor to produce anti-inflammatory, anti-fibrotic, vasodilatory, insulin-sensitizing, and organ-protective effects that directly oppose the pathological actions of the ACE/Ang II/AT1R axis.
Think of the renin-angiotensin system as a city's emergency response network. Ang II is the aggressive fire department that responds to threats by flooding the area with water (vasoconstriction), boarding up windows (fibrosis), and evacuating residents (insulin resistance) β effective in crisis but destructive if it never stands down. Ang 1-7 is the restoration crew that follows behind: opening streets back up (vasodilation), removing boards (anti-fibrosis), repairing water damage (anti-inflammatory cleanup), and helping residents move back in (insulin sensitivity). ACE2 is the dispatcher deciding when to call the restoration crew instead of the fire brigade. In health, these teams alternate seamlessly. In chronic disease (diabetes, hypertension, COVID-19), the fire department runs 24/7 while the restoration crew never gets called β the city stays boarded up, flooded, and inflamed even though the original emergency is long over. Clinical interventions that boost ACE2 or Ang 1-7 essentially tell the dispatcher: "Stop calling the fire department, send restoration."
Ang 1-7 is synthesized through two parallel pathways controlled by ACE2:
Pathway 1: angiotensin I β ACE2 β Angiotensin-(1-9) β ACE2 β Ang 1-7
Pathway 2: Ang II β ACE2 β Ang 1-7
Once formed, Ang 1-7 binds the MAS receptor, a G-protein coupled receptor (GPCR) expressed in lungs, heart, brain, kidneys, adipose tissue, pancreatic Ξ²-cells, gonads, skeletal muscle, and vascular endothelium. MAS receptor activation triggers:
- Anti-inflammatory cascade: MAS β inhibition of NF-ΞΊB nuclear translocation β suppression of IL-1Ξ², IL-6, TNF-Ξ± β reduced C-reactive protein and acute phase proteins β decreased systemic inflammation
- Anti-fibrotic signaling: MAS β suppression of TGF-Ξ²1/Smad3 pathway β reduced collagen synthesis by fibroblasts β prevention of tissue remodeling and organ fibrosis
- Vasodilatory response: MAS β activation of eNOS (endothelial nitric oxide synthase) β increased Nitric Oxide production β vascular smooth muscle relaxation β reduced blood pressure
- Metabolic reprogramming: MAS β activation of AKT pathway and AMPK β translocation of GLUT4 transporters to cell membrane β insulin-independent glucose uptake β enhanced insulin sensitivity β suppression of lipolysis in white adipose, promotion of lipolysis and beta-hydroxybutyrate production in brown adipose
- Anti-oxidative protection: MAS β upregulation of SOD (superoxide dismutase) and catalase β reduction of Reactive Oxygen Species β decreased oxidative stress
The pathway operates as a yin-yang system with the ACE/Ang II/AT1R axis β they share the same precursor (angiotensin I) but produce opposite effects:
graph TD
A[Angiotensinogen] -->|Renin| B[Angiotensin I]
B -->|ACE| C[Angiotensin II]
B -->|ACE2| D[Angiotensin 1-9]
D -->|ACE2| E[Ang 1-7]
C -->|ACE2| E
C -->|AT1R| F["Vasoconstriction<br/>Inflammation<br/>Fibrosis<br/>Insulin Resistance"]
E -->|MAS Receptor| G["Vasodilation<br/>Anti-inflammation<br/>Anti-fibrosis<br/>Insulin Sensitivity"]
style F fill:#ffcccc
style G fill:#ccffcc
Tissue-specific effects through the same MAS receptor:
- Lungs: Prevention of pulmonary edema, reduction of ARDS severity, suppression of fibroblast activation
- Heart: Anti-hypertrophic signaling, reduction of post-infarct remodeling, improved ejection fraction
- Pancreas: Ξ²-cell protection from glucotoxicity, enhanced insulin secretion in response to glucose
- Adipose: Increased glucose uptake, reduced adipocyte hypertrophy, suppression of macrophage infiltration
- Brain: Reduced neuroinflammation, improved cerebral blood flow, neuroprotection in stroke
- Kidneys: Reduced glomerular hyperfiltration, decreased proteinuria, prevention of diabetic nephropathy
- Gonads: Increased testosterone and estrogen synthesis, improved ovulation and spermatogenesis
The ACE2/Ang 1-7/MAS axis represents one of the most therapeutically relevant pathways in cPNI because it connects all five metamodels through a single molecular lever:
Metamodel relevance:
- Stress axis: Chronic cortisol suppresses ACE2 expression, shifting balance toward pro-inflammatory Ang II β explains stress-induced hypertension and insulin resistance
- Immune tolerance: MAS receptor activation suppresses NF-ΞΊB and pro-inflammatory cytokines β central to resolution of chronic low-grade inflammation
- Metabolic flexibility: Ang 1-7 enhances glucose uptake independent of insulin, bypasses insulin resistance β critical for metabolic rescue in Type 2 Diabetes
- Gut-brain axis: MAS receptors in circumventricular organs and area postrema allow peripheral Ang 1-7 to influence central appetite regulation and autonomic tone
- Evolutionary mismatch: The ACE2/Ang 1-7 pathway evolved to protect against acute stressors (infection, injury) but becomes chronically suppressed in modern environments (sedentarism, processed foods, chronic stress)
Clinical thresholds and biomarkers:
- ACE2 activity is reduced in obesity, diabetes, hypertension, and aging (mechanism behind increased COVID-19 severity in these populations)
- Ang II/Ang 1-7 ratio >3.0 indicates pathway imbalance and predicts cardiovascular events
- Therapeutic goal: increase ACE2 activity or directly supplement Ang 1-7 analogs
Patient populations where this pathway is central:
Intervention strategies:
- Pharmacological: ACE inhibitors (indirect β prevent Ang IβAng II conversion, sparing substrate for ACE2 pathway), ARBs (block AT1R, increase ACE2 expression as compensatory response), direct Ang 1-7 analogs (under development)
- Lifestyle: Exercise upregulates ACE2 expression in skeletal muscle and adipose tissue, intermittent fasting increases ACE2/AT1R ratio, omega-3 fatty acids enhance MAS receptor sensitivity
- Nutraceutical: Resveratrol and quercetin increase ACE2 expression, Curcumin enhances MAS receptor signaling, vitamin D upregulates ACE2 transcription
Exam-critical concept: Understanding why ACE inhibitors and ARBs reduce mortality beyond blood pressure control β they shift the entire inflammatory, metabolic, and fibrotic balance through the ACE2/Ang 1-7 axis. This is the molecular explanation for the pleiotropic benefits of RAAS blockade.
- Ang 1-7 is a heptapeptide (7 amino acids) with sequence: Asp-Arg-Val-Tyr-Ile-His-Pro
- Produced by ACE2 from either angiotensin I or Ang II β ACE2 is the rate-limiting enzyme
- Binds exclusively to MAS receptor (encoded by MAS1 gene), a G-protein coupled receptor discovered in 2003
- MAS receptor expressed in virtually every tissue: heart (cardiomyocytes, endothelium), lungs (alveolar epithelium), brain (hypothalamus, brainstem), kidneys (podocytes, mesangial cells), pancreas (Ξ²-cells), adipose (adipocytes, macrophages), gonads (Leydig cells, granulosa cells)
- Opposes all pathological effects of Ang II: where Ang II causes vasoconstriction, inflammation, fibrosis, oxidative stress, insulin resistance, and cell proliferation, Ang 1-7 produces vasodilation, anti-inflammation, anti-fibrosis, anti-oxidation, insulin sensitivity, and cell differentiation
- Plasma Ang 1-7 levels: 5-15 pmol/L in healthy individuals, <5 pmol/L in metabolic syndrome and diabetes
- Ang II/Ang 1-7 ratio is a better predictor of cardiovascular risk than either peptide alone (healthy ratio <2.0, pathological >3.0)
- Half-life in circulation: ~10-30 seconds (rapidly degraded by ACE and aminopeptidases) β requires continuous production for sustained effects
- COVID-19 severity directly correlates with ACE2 downregulation by SARS-CoV-2 spike protein binding β loss of Ang 1-7 production β unopposed Ang II effects β cytokine storm, pulmonary edema, myocarditis
- Exercise-induced increases in ACE2/Ang 1-7 explain part of the anti-inflammatory and insulin-sensitizing effects of physical activity (MAS receptor activation in skeletal muscle after a single bout)
- Gender difference: Women have higher baseline ACE2 expression (estrogen upregulates ACE2 transcription) β higher Ang 1-7 levels β protection from hypertension and cardiovascular disease pre-menopause
- ACE2 β the enzyme that produces Ang 1-7 from angiotensin I or Ang II; SARS-CoV-2 binds and downregulates this enzyme
- angiotensin I β 10-amino-acid precursor cleaved by ACE2 to produce angiotensin 1-9, then Ang 1-7
- Ang II β the pro-inflammatory, pro-fibrotic peptide that ACE2 converts into Ang 1-7; balance between these two determines tissue fate
- MAS receptor β the exclusive receptor for Ang 1-7; GPCR that mediates all protective downstream effects
- NF-ΞΊB β master inflammatory transcription factor suppressed by MAS receptor activation
- ACE inhibitors β medications like lisinopril and enalapril that shift RAAS balance toward Ang 1-7 by blocking Ang IβAng II conversion
- RAA-system β the overarching endocrine cascade; Ang 1-7 represents the counter-regulatory "brake" on this system
- insulin resistance β reduced by Ang 1-7 through AKT/AMPK activation and GLUT4 translocation independent of insulin receptor
- insulin sensitivity β enhanced by MAS receptor signaling in muscle, adipose, and liver
- GLUT4 transporters β translocated to cell membrane by Ang 1-7/MAS signaling, enabling insulin-independent glucose uptake
- lipolysis β context-dependent: suppressed in white adipose (anti-inflammatory), promoted in brown adipose (thermogenesis)
- Type 2 Diabetes β characterized by suppressed ACE2 and low Ang 1-7; MAS receptor activation bypasses insulin resistance
- ARDS β acute respiratory distress syndrome prevented by Ang 1-7 through reduction of pulmonary edema and neutrophil infiltration
- COVID-19 β viral spike protein binds ACE2, reducing enzyme availability for Ang 1-7 production; severity correlates with Ang II/Ang 1-7 imbalance
- chronic low-grade inflammation β driven by unopposed Ang II signaling when ACE2/Ang 1-7 pathway is suppressed
- atherosclerosis β reduced by Ang 1-7 through suppression of endothelial activation, foam cell formation, and plaque inflammation
- Fibrosis β prevented in all tissues (lung, heart, kidney, liver) through MAS receptor suppression of TGF-Ξ²1/Smad3 pathway
- Nitric Oxide β production increased by Ang 1-7 through eNOS activation, mediating vasodilation and endothelial protection
- Reactive Oxygen Species β reduced by MAS receptor upregulation of antioxidant enzymes (SOD, catalase)
- Exercise β upregulates ACE2 expression in skeletal muscle and adipose, increasing Ang 1-7 production as part of exercise's anti-inflammatory effects
- Metabolic syndrome β characterized by low Ang 1-7, high Ang II, and high Ang II/Ang 1-7 ratio; restoring balance is therapeutic target
- Obesity β suppresses ACE2 expression in adipose tissue, reducing local Ang 1-7 production and promoting adipose inflammation
- Testosterone β synthesis increased by MAS receptor activation in Leydig cells; Ang 1-7 enhances spermatogenesis
- Cardiovascular disease β pathogenesis involves ACE2 deficiency and loss of Ang 1-7 protective effects; restoring pathway reduces mortality
- Chronic Kidney Disease β progression slowed by Ang 1-7 through reduction of glomerular hyperfiltration, mesangial expansion, and podocyte injury